What records are connected here?
- Evidence lanes
- 3
- Source years
- 5
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsCancer
Motixafortide is a lab-made cyclic peptide that blocks the CXCR4 receptor. It is the active ingredient in Aphexda.1,2 Aphexda is approved, together with filgrastim (G-CSF), to move blood stem cells from the bone marrow into the bloodstream so they can be collected for a transplant of a patient’s own cells in multiple myeloma.1 In the randomized, placebo-controlled GENESIS trial of 122 patients described in the label, 67.5% given motixafortide and 9.5% given placebo reached the stem cell collection goal.1
| What it is | A synthetic cyclic peptide that inhibits the chemokine receptor CXCR4, used to mobilize blood-forming stem cells, according to the Aphexda label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Aphexda, NDA 217159, with an original approval date of September 8, 2023. The cited label has no boxed warning.1,2 |
| Human evidence | One randomized, double-blind, placebo-controlled trial (GENESIS) in 122 patients with multiple myeloma, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Motixafortide is a synthetic cyclic peptide of 14 amino acids, including citrulline and a naphthylalanine, closed by a disulfide bond, according to the label.1
In the United States it is the active ingredient of Aphexda, approved under NDA 217159, according to Drugs@FDA.2
The label states that motixafortide blocks the CXCR4 receptor so that its signal, CXCL12, cannot bind. CXCR4 helps anchor blood-forming stem cells in the bone marrow, so blocking it releases them into the blood.1
GENESIS, described in the label, randomized 122 patients with multiple myeloma to motixafortide (80 patients) or placebo (42), all after several days of filgrastim.1
The collection goal was reached within up to two collection sessions by 67.5% of patients given motixafortide and 9.5% given placebo, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Aphexda, application NDA 217159, with an original approval date of September 8, 2023.2
The Aphexda label cited here (DailyMed SPL version 3, published October 19, 2026) states that it is indicated in combination with filgrastim to mobilize blood stem cells for collection and transplant of a patient’s own cells in multiple myeloma.1
The label has no boxed warning. Its warnings include anaphylactic shock and other allergic reactions, which it states call for premedication and a setting where they can be treated, and the possibility of mobilizing leukemia cells.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Motixafortide is not among them.3,4
How it compares with other stem cell mobilizers: the trial described in the label compared it only with placebo, both added to filgrastim.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Motixafortide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Motixafortide are a bounded selection, not every registration or paper about Motixafortide. For the years before Motixafortide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Motixafortide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Motixafortide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Aphexda for stem cell mobilization in multiple myeloma. In a randomized, placebo-controlled trial of 122 patients described in the label, far more patients reached the stem cell collection goal with motixafortide. The label warns of anaphylactic shock.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Aphexda for stem cell mobilization in multiple myeloma. In a randomized, placebo-controlled trial of 122 patients described in the label, far more patients reached the stem cell collection goal with motixafortide. The label warns of anaphylactic shock.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.↗Source date November 9, 2026Literature metadata · added November 16, 2026
Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.↗Source date November 9, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06506461↗Source date October 15, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.
9 of 9 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.
9 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Selected records span April 1, 2022 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Literature metadata
PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Literature metadata
PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.↗
Literature metadata
PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026